Avadel Pharmaceuticals/AVDL

$18.09

4.56%
-
1D1W1MYTD1YMAX

About Avadel Pharmaceuticals

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Ticker

AVDL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Gregory Divis

Employees

154

Headquarters

Dublin, Ireland

AVDL Metrics

BasicAdvanced
$1.57B
Market cap
-
P/E ratio
-$2.04
EPS
1.61
Beta
-
Dividend rate
$1.57B
1.61107
$18.85
$9.50
1.24M
3.641
3.36
-13.94%
-107.75%
-481.76%
-156.49%
56.135
17.753
22.139
11.18%
7.78%

What the Analysts think about AVDL

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 10 analysts.
26.59% upside
High $29.00
Low $19.00
$18.09
Current price
$22.90
Average price target

AVDL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-147.93% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$19.4M
177.14%
Net income
$-28.7M
-20.72%
Profit margin
-147.93%
-71.39%

AVDL Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 11.83%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.48
-$0.83
-$0.41
-$0.29
-
Expected
-$0.38
-$0.38
-$0.37
-$0.26
-$0.21
Surprise
27.36%
115.98%
10.14%
11.83%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Avadel Pharmaceuticals stock?

Avadel Pharmaceuticals (AVDL) has a market cap of $1.57B as of April 24, 2024.

What is the P/E ratio for Avadel Pharmaceuticals stock?

The price to earnings (P/E) ratio for Avadel Pharmaceuticals (AVDL) stock is 0 as of April 24, 2024.

Does Avadel Pharmaceuticals stock pay dividends?

No, Avadel Pharmaceuticals (AVDL) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next Avadel Pharmaceuticals dividend payment date?

Avadel Pharmaceuticals (AVDL) stock does not pay dividends to its shareholders.

What is the beta indicator for Avadel Pharmaceuticals?

Avadel Pharmaceuticals (AVDL) has a beta rating of 1.61. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Avadel Pharmaceuticals stock price target?

The target price for Avadel Pharmaceuticals (AVDL) stock is $22.9, which is 26.59% above the current price of $18.09. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Avadel Pharmaceuticals stock

Buy or sell Avadel Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing